Jazz Pharmaceuticals (JAZZ) Accounts Payables (2010 - 2026)

Jazz Pharmaceuticals' Accounts Payables history runs 17 years deep, the most recent figure standing at $100.0 million for Q1 2026.

• In Q1 2026, Accounts Payables rose 4.24% year-over-year to $100.0 million; the TTM figure through Mar 2026 stood at $100.0 million (up 4.24% YoY), while the FY2025 annual figure was $122.1 million, up 56.8% from the prior year.
• Accounts Payables was $100.0 million for Q1 2026 at Jazz Pharmaceuticals, down from $122.1 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $152.2 million in Q3 2025 to a low of $73.3 million in Q1 2022.
• Historically, Accounts Payables has averaged $98.7 million across 5 years, with a median of $97.1 million in 2024.
• The sharpest annual moves came in 2024 and 2025: Accounts Payables plunged 35.45% in 2024, then surged 78.2% in 2025.
• A 5-year view of Accounts Payables shows it stood at $90.8 million in 2022, then rose by 13.21% to $102.8 million in 2023, then retreated by 24.22% to $77.9 million in 2024, then soared by 56.8% to $122.1 million in 2025, then declined by 18.1% to $100.0 million in 2026.
• The last three Accounts Payables figures came in at $100.0 million (Q1 2026), $122.1 million (Q4 2025), and $152.2 million (Q3 2025), per Business Quant data.